Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net loss	$ (201,592)	$ (197,723)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	575	620
Stock-based compensation	45,025	24,133
Issuance of PIK interest debt	3,583	3,484
Accrued interest on revenue interest financing liability	24,727	14,079
Amortization of debt discount	1,877	2,110
Other	1,869	1,329
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(8,067)	(1,860)
Accounts receivable, net	(1,637)	0
Accounts payable and accrued expenses (includes changes in related party amounts of $184 and $1,139, respectively)	6,410	8,679
Accrued clinical trial expenses	0	(1,402)
Accrued interest	292	377
Operating right-of-use assets and lease liabilities	194	(238)
Inventory	(9,442)	0
Other long-term assets	(1,394)	(118)
Net cash used in operating activities	(137,580)	(146,530)
Cash flows from investing activities
Cash paid for property, plant and equipment	(1,634)	(1,041)
Net cash used in investing activities	(1,634)	(1,041)
Cash flows from financing activities
Proceeds from issuance of common stock from exercise of stock options	124	0
Net proceeds from issuance of debt	39,318	0
Net proceeds from underwritten public offering	141,390	0
Net proceeds from revenue interest financing transaction	172,675	95,446
Net cash provided by financing activities	367,580	120,042
Net increase (decrease) in cash and cash equivalents and restricted cash	228,366	(27,529)
Cash and cash equivalents and restricted cash - beginning of period	155,890	183,419
Cash and cash equivalents and restricted cash - end of period	384,256	155,890
Supplemental disclosure of cash flow information
Interest paid	11,133	7,033
Supplemental disclosure of noncash investing and financing activities
Property and equipment purchases included in accounts payable and accrued expenses	18	138
Final interest payment fee	2,200	0
Settlement of ESPP liability in common stock	1,417	909
Settlement of 401(k) liability in common stock	1,612	1,116
Operating lease liabilities arising from obtaining right-of-use assets		554
At-the-Market Offering Program
Cash flows from financing activities
Net proceeds from issuance of common stock	$ 14,073	$ 24,596